Neoadjuvant Immunotherapy Of Cisplatin Ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Neoadjuvant Immunotherapy Of Cisplatin Ineligible High Risk Upper Urinary Tract Urothelial Carcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

CompletedPhase 2

NCT04672330

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies. This study is desi…

China16 participantsStarted 2020-12-01

Treatment: Tislelizumab